ALK and non-small cell lung carcinoma: In a phase II clinical trial (NCT04603287), researchers enrolled 55 patients with locally advanced or metastatic EGFR/anaplastic lymphoma kinase (ALK) wild-type NSCLC who had failed first-line anti-PD-1/L1 therapy with or without platinum-based chemotherapy (PBC) to receive SI-B001 combined with docetaxel (70).